ArticleJournal of cancer research and clinical oncology2003
Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients.
Article in Journal of cancer research and clinical oncology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 134 citations in OpenAlex.
- Alterations of dendritic cell subsets in the peripheral circulation of patients with cervical carcinoma.Journal of experimental & clinical cancer research : CR · 2010Trial
- Antigen-Presentation Competence in Gynecologic Cancers: Mechanisms, Evidence and Translational Priorities.Cells · 2026Review
- The current landscape of therapeutic vaccination approaches for treatment of HPV-dependent malignancies.NPJ vaccines · 2026Review
- Advances in immunotherapy for HPV-associated malignancies: emerging strategies and clinical progress.Frontiers in immunology · 2026Review
- Leveraging oncovirus-derived antigen against the viral malignancies in adoptive cell therapies.Biomarker research · 2024Review
- HPV pathogenesis, various types of vaccines, safety concern, prophylactic and therapeutic applications to control cervical cancer, and future perspective.Virusdisease · 2023Review
- Molecular mechanisms augmenting resistance to current therapies in clinics among cervical cancer patients.Medical oncology (Northwood, London, England) · 2023Review
- EDA-E7 Activated DCs Induces Cytotoxic T Lymphocyte Immune Responses against HPV Expressing Cervical Cancer in Human Setting.Vaccines · 2023Article
- Review
- Immunotherapy for Cervical Cancer: Are We Ready for Prime Time?International journal of molecular sciences · 2022Review
- Efficacy and Safety of Immunotherapy for Cervical Cancer-A Systematic Review of Clinical Trials.Cancers · 2022Review
- Article
- The dawn of vaccines for cancer prevention.Nature reviews. Immunology · 2018Review
- A comprehensive in silico analysis for identification of therapeutic epitopes in HPV16, 18, 31 and 45 oncoproteins.PloS one · 2018Article
- Regulatory T Cells in Gynecologic Cancer.MOJ immunology · 2018Article
- The Role of the Insulin-Like Growth Factor 1 Pathway in Immune Tumor Microenvironment and Its Clinical Ramifications in Gynecologic Malignancies.Frontiers in endocrinology · 2018Article
- Dendritic cell based vaccination strategy: an evolving paradigm.Journal of neuro-oncology · 2017Review
- Therapeutic options for treatment of human papillomavirus-associated cancers - novel immunologic vaccines: ADXS11-001.Gynecologic oncology research and practice · 2017Review
- Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies.Expert review of vaccines · 2016Review
- Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases.Human vaccines & immunotherapeutics · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeHuman papillomavirus (HPV) type 16 and 18 are the most prevalent genotypes in cervical cancer. The viral oncoproteins E6 and E7 are considered to be tumor-specific targets for immunotherapy. HPV E7 antigen-loaded autologous dendritic cells (DC) were evaluated as cellular tumor vaccine in a case series of cervical cancer patients.
methodsAutologous monocyte-derived DCs were pulsed with recombinant HPV16 E7 or HPV18 E7 oncoprotein and administered to 15 stage IV cervical cancer patients. Safety, toxicity, and induction of serological and cellular immune responses were monitored.
resultsThe vaccine was well-tolerated and no local or systemic side effects or toxicity were recorded. A specific serologic response was seen in 3/11 evaluated patients. Specific cellular immune responses (4/11) were detected with 2/10 positive de novo reactions plus one boosted preexistent response in proliferation assays and 3/11 in IFN-gamma ELISpot assays. A transient drop in tumor marker SCC was observed in 5/9 evaluable patients but did not correlate with markers of the immune response. No objective clinical response was observed. Tumor biopsies available from four patients showed severe or complete loss of HLA expression in three of the advanced tumors.
conclusionAutologous dendritic cells pulsed with HPV E7 protein can induce T cell responses in a portion of late stage cervical cancer patients. Boosting of immune responses by adjuvants and vaccination of tumor HLA-positive patients will be mandatory in future trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.